US government concedes defeat in Utah Medical vs FDA fight:
This article was originally published in Clinica
Executive Summary
In what signals the unequivocal close of an ugly chapter in Utah Medical's history, the company has received confirmation from the US Department of Justice that the government will not appeal a recent court ruling that dismissed all FDA charges against the company. The Salt Lake City, Utah-based developer of women's and paediatric specialty medical devices saw the end of its four-year battle with the regulatory authority in October when a district court found Utah to be in compliance with federal quality systems regulations, and not in violation, as the FDA had doggedly claimed.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.